Efficacy of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate in therapy of equine abortion virus-induced hepatitis in hamsters.
Equine abortion virus (EAV)-induced hepatitis in hamsters presents an interesting animal model for the evaluation of drugs possessing anti-deoxyribonucleic acid virus activity. These experiments demonstrate that 9-beta-d-arabinofuranosylhypoxanthine 5'-monophosphate (ara-HxMP), a new synthetic, water-soluble, antiviral agent, effectively controls this disease in hamsters with a therapeutic index of approximately 60. Ara-HxMP prevented hepatitis-associated deaths in hamsters, reduced the titer of EAV developing in hamsters, and inhibited the increase of serum glutamic pyruvic transaminase in EAV-infected hamsters.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001089:Arabinose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006224:Cricetinae; D005260:Female; D006506:Hepatitis A / Q000188:drug therapy* / Q000382:microbiology; D006564:Herpesviridae; D004861:Herpesvirus 1, Equid / Q000302:isolation & purification; D007291:Inosine Monophosphate / Q000627:therapeutic use*; D007292:Inosine Nucleotides / Q000627:therapeutic use*; D008099:Liver / Q000382:microbiology; D013997:Time Factors; D014740:Vidarabine / Q000627:therapeutic use
D000998:Antiviral Agents; D007292:Inosine Nucleotides; D007291:Inosine Monophosphate; D001089:Arabinose; D000410:Alanine Transaminase; D014740:Vidarabine